AgelessRx announced it has raised $12 million in a pre-seed funding round led by longevity investor Joshua Rosenthal. According to the company, the capital will be used to advance clinical research, develop new longevity-focused products and grow its telemedicine platform.
The company said the funding will help accelerate ongoing clinical trials, including studies investigating the potential of rapamycin and other interventions targeting biological aging. AgelessRx claims its approach centers on translating scientific research into accessible therapies that address age-related decline before disease develops.
According to the company, part of the investment will also support technology enhancements to its online platform, which offers prescription and non-prescription treatments aimed at extending healthspan. AgelessRx said it plans to broaden its product pipeline with additional compounds supported by emerging evidence in the longevity field.
The company claims its platform is designed to deliver preventive interventions directly to consumers, combining digital health tools with clinician oversight. AgelessRx noted that the new funding positions it to scale operations and expand its reach within the growing longevity market.
AgelessRx said it remains focused on its mission to make evidence-based longevity therapies more widely available, aiming to help users reduce biological age and maintain long-term health.
